GHRP-6 – Kodiac biolabs

Plain-language summaryIntrigue 58 / 100

GHRP-6 is the original growth hormone releasing peptide and a strong appetite stimulant (because it activates the ghrelin receptor that controls hunger). It produces robust growth hormone release but with the most pronounced cortisol and prolactin elevation among the GHRPs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

32/100

First-generation GHRP largely superseded by cleaner alternatives, appetite signal is interesting but not enough

Look, GHRP-6 has a story, but its best chapters were written in the 1990s. It’s a first-generation hexapeptide, one of the original compounds that validated the ghrelin receptor as a viable target for GH secretagogues, and for that it deserves some historical respect. But history isn’t a research rationale.

The mechanism is exactly what you’d expect from something this old: GHSR1a agonism, pulsatile GH release, appetite stimulation through the ghrelin pathway. Solid, well-understood, extensively mapped. The problem is it also drags cortisol and prolactin up in a way that the later-generation GHRPs largely avoid. Ipamorelin came along specifically to solve that problem. Researchers moved on. The cortisol/prolactin elevation isn’t just a safety nuisance in animal models, it complicates any experiment where you’re trying to isolate GH-axis effects. That’s a real methodological liability.

Differentiation is where GHRP-6 genuinely suffers. We think of it mostly as a less clean GHRP-2 or a more side-effect-prone ipamorelin. There’s almost no scenario where it’s the first choice over those two unless you’re specifically studying appetite modulation via ghrelin, which is the one corner where GHRP-6 has a distinctive profile. The appetite stimulation is pronounced and reproducible, and if thats the actual research question, it becomes a relevant tool. Cachexia or sarcopenia models where caloric intake is the outcome variable, for instance. But that is a narrow carve-out, not a broad program.

Evidence quality is moderate. Decades of multi-lab preclinical data exist, and there’s some human work from the 1990s and early 2000s on GH secretion dynamics. But clinical development stalled out, and theres essentially no modern RCT infrastructure behind it. The human translational story is capped by that abandoned trajectory. We’re not looking at a compound with fresh phase 2 data or a revived indication pipeline. What we’re looking at is a reference compound for ghrelin receptor agonism that has been functionally replaced in most experimental designs.

The bench value survives in one specific context: if you’re running a comparative GHRP study and need a first-generation reference point, or if appetite/orexigenic signaling is central to your model, GHRP-6 earns its spot. Outside that, we’d suggest the investigator ask whether ipamorelin or GHRP-2 actually answers their question better before reaching for this one. Most of the time, the answer is yes. That’s the honest position here: not a bad compound, just not the right compound for most research programs that have access to better options.

Novelty: 22
Mechanism promise: 35
In-category differentiation: 22
Evidence quality: 45
Translational signal: 35
Research bench value: 38

Rationale GHRP-6 scores low on novelty and differentiation because it predates and is functionally inferior to later GHRPs on most axes; the cortisol/prolactin liability killed its clinical trajectory and ipamorelin has taken its place as the reference clean GHRP. The appetite/ghrelin angle is genuinely distinctive and gives it marginal bench value, but the evidence base is messy and the compound just isn’t a priority for any serious program in 2025.

Growth hormone releasing peptide / ghrelin receptor agonist

A first-generation hexapeptide ghrelin receptor agonist with prominent appetite stimulation, often used as a research-grade alternative to ipamorelin.

Abstract

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2; CAS 87616-84-0; molecular formula C46H56N12O6; molecular weight 873.02) is a first-generation hexapeptide ghrelin receptor agonist. The compound stimulates GH release with kinetics similar to GHRP-2 but produces more pronounced cortisol and prolactin elevation, which has limited its clinical development. GHRP-6 also produces marked appetite stimulation through ghrelin pathway activation, an effect that distinguishes it from later GHRPs and that may be either useful (cachexia, sarcopenia adjunct) or unwanted (weight management contexts) depending on the application. Pharmacokinetics: plasma half-life 15 to 60 minutes; parenteral administration only. Research-grade doses are typically 100 to 300 micrograms subcutaneously per administration.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-077Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.